Amazon affiliate link
Alcohol pads
MED PRIDE, 70% isopropyl, 200 count per listing. An alcohol pad does not establish sterility of a research product.
View on Amazon ↗Growth hormone research
Tesamorelin
research guide
Tesamorelin is a synthetic analog of growth hormone releasing hormone that stimulates the pituitary to release growth hormone. The EGRIFTA SV label describes its approved use for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight loss [3]. Secondary analyses of clinical trial cohorts reported changes in muscle composition and fat density in treatment responders [1][2]. Reign research vials are a separate product and are not the approved EGRIFTA SV formulation.
Evidence depends on population and formulation. Literature summary, not clinical peer review.
Looking for the product? Reign listings and business disclosure ↓
Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.
01 · Start with identity
What is Tesamorelin?
Tesamorelin the approved drug is a specific peptide sequence manufactured and dosed as Egrifta by its FDA-approved sponsor for a narrow HIV lipodystrophy indication. Reign Peptide's tesamorelin vials are labeled as a research chemical of the same peptide sequence sold for laboratory use, not the approved drug product, with no confirmed manufacturing or bioequivalence link to Egrifta.
Also searched as: Egrifta, TH9507, growth hormone releasing hormone analog
02 · Read the evidence
What the studies reported
01
Muscle fat and area in tesamorelin responders
A secondary, exploratory analysis of two completed randomized (2:1) trials in HIV-positive adults with abdominal obesity, restricted to tesamorelin responders (visceral fat decrease of 8% or more), used CT scans of trunk muscles to assess muscle density and area; the analysis is described by its authors as exploratory rather than a primary trial endpoint. [1]
02
Fat quality independent of fat quantity
In a separate analysis of participants from the same two placebo-controlled trials (193 tesamorelin responders and 148 placebo-treated participants, 87% male), fat density on CT scan, a marker of adipocyte quality, changed with tesamorelin treatment in ways not fully explained by the amount of visceral fat lost. [2]
03 · Numbers in context
What does dosing evidence actually support?
Published evidence comes from two multicenter, randomized, placebo-controlled phase 3 trials in 806 HIV-infected adults with abdominal obesity, using the FDA-approved EGRIFTA SV once-daily subcutaneous injection under clinical supervision, with visceral fat response defined by the FDA as at least an 8% reduction on CT scan [3]. This is disease-specific efficacy and safety data for an approved pharmaceutical product in a defined patient population; it does not describe a general wellness or off-label dosing protocol for a research-labeled peptide vial, and this page does not restate the specific milligram dosing from the product label.
A study dose is not a personal dose. Population, route, formulation and supervision are part of the result. Online community schedules are not treated here as established clinical protocols.
04 · Safety and limits
What not to overlook
- Tesamorelin (EGRIFTA SV) is FDA approved only for reduction of excess abdominal fat in HIV-associated lipodystrophy, under medical supervision; per its official label it is not indicated for general weight loss and has a weight-neutral effect.
- The FDA label lists contraindications including disruption of the hypothalamic-pituitary axis, active malignancy, and pregnancy.
- Research-labeled tesamorelin vials are not the approved EGRIFTA SV formulation and carry no equivalent manufacturing oversight or clinical safety data.
- Fat quality and muscle findings summarized here come from secondary, exploratory analyses of the pivotal trial cohorts, not independent confirmatory studies [1][2].
05 · Product distinctions
Names are not interchangeable
EGRIFTA SV is an FDA-approved, prescription, subcutaneously injected tesamorelin formulation manufactured under pharmaceutical GMP standards; per its FDA label it is a distinct formulation and dosing strength from the earlier EGRIFTA product, with different reconstitution and storage requirements between the two. Reign Peptide sells tesamorelin as a separate lyophilized powder vial (10mg or 20mg) for laboratory research use, reconstituted by the buyer; this is a distinct product from either approved drug formulation, and no clinical trial referenced here used that research product.
06 · Handling and storage
Follow validated product instructions
A single water volume, refrigerator temperature or expiry window cannot be assumed for every compound and formulation. Use the exact manufacturer documentation and a validated laboratory procedure. If stability, solvent compatibility or microbiological quality is not documented, those properties remain unverified.
Refrigeration, clear appearance and bacteriostatic water do not make an unverified research product suitable for injection. This guide does not provide a mixing or administration procedure.
The existing concentration calculator checks arithmetic only. It cannot choose a safe dose or establish compatibility, sterility or shelf life.
Reign Peptide · Business disclosure
Research product listings
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.
Supplies and accessories
Compare the actual specifications
Jorge's supply directory includes syringes, alcohol pads, storage cases, travel refrigeration and electrolytes, with separate links for the two travel refrigeration options. Accessory availability is not a recommendation to administer a research compound.
Affiliate disclosure: As an Amazon Associate I earn from qualifying purchases.
Amazon affiliate link
Peptide fridge case
Listing: 63 slots for 3mL bottles, bag only. An organizer is not active refrigeration or a validated storage system.
View on Amazon ↗Amazon affiliate link
Peptide travel case
Medineed travel case with temperature display and two ice packs per listing. Check dimensions and transport requirements.
View on Amazon ↗Questions still worth asking
What remains unresolved?
- Do the visceral fat and fat-quality benefits seen in HIV lipodystrophy trials generalize to populations without HIV-associated fat redistribution?
- What is the comparative purity and biological activity of unapproved research-grade tesamorelin versus the approved Egrifta drug substance?
Check the source
References and evidence scope
- Human trial · 2019The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV ↗
- Human trial · 2021Tesamorelin improves fat quality independent of changes in fat quantity ↗
- Official label · 2026EGRIFTA SV (tesamorelin) for injection, kit label ↗
These are the sources reviewed for this page, not an exhaustive systematic review. Related compound research is identified as such. Product links are not scientific references.
Keep reading